Engineered receptor-biased IL-2–drug immunoconjugates selectively expand Tregs and suppress effector cells for autoimmune therapy

Cell Reports Medicine · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles